Development of a novel lipase inhibitor for the treatment of acute pancreatitis
Active Project Grant Awarded Last action
- Award ID
- R44DK125219
- Recipient
-
Lamassu Pharma LLC UEI RB6PG7UNAKE3
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,340,363
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date 90% complete
- Originally
- Funding
-
- $4,261,943.00 Federal
- $78,420.00 Non-federal
- Place of performance
- Durham, NC 27705, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $865,872 | $0 | |
| Amendment | $866,665 | $0 | |
| Amendment | $873,744 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $78,420 | $0 | |
| Amendment | $78,420 | $78,420 | |
| Original award | $1,498,822 | $0 |
Quick answers
Who received award R44DK125219?
R44DK125219 was awarded to Lamassu Pharma LLC by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on July 7, 2020.
How much is award R44DK125219 worth?
$4,340,363 has been obligated on R44DK125219: $4,261,943 in federal funding and $78,420 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award